News

Jerusalem, Israel, January 1, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg. Upon final approval, Teva's Simvastatin Tablets will be the AB-rated generic equivalent of Merck's Zocor® Tablets, a product indicated for the treatment of high cholesterol. The brand product has annual sales of approximately $4.4 billion.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceuti Read More »

Jerusalem, Israel, January 1, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Divalproex Sodium Delayed-Release Tablets USP, 125 mg, 250 mg and 500 mg. Final approval of this product is anticipated upon expiration of patent protection for the brand product in January 2008.Upon final approval, Teva's Divalproex Sodium Delayed-Release Tablets will be the AB-rated generic equivalent of Abbott's Depakote® Tablets. This product is indicated for treatment of manic episodes a Read More »

Jerusalem, Israel and Miami, Florida, January 3, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) issued the following statement regarding IVAX' outstanding 1.5% Convertible Senior Notes due 2025, in connection with Teva's pending acquisition of IVAX:With Teva's approval, IVAX has declined to elect the "public acquirer fundamental change" option with respect to such notes. Accordingly, holders of any of these notes that remain outstanding following consummation of the merger will have the option to convert their notes and collect the "ma Read More »

Jerusalem, Israel and Miami, Florida, January 10, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) announced today that the closing date of the merger has been rescheduled and will take place on the third business day following their public announcement that the U.S. Federal Trade Commission ("FTC") has accepted the consent order which Teva and IVAX have signed. The transaction cannot be closed without the acceptance of the consent order by the Commissioners of the FTC, and such acceptance has not as yet been obtained. The FTC review of the c Read More »

Jerusalem, Israel and Miami, Florida, January 23, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) announced today that the U.S. Federal Trade Commission ("FTC") has accepted the proposed consent order for public comment and granted early termination of the Hart Scott Rodino waiting period, thereby permitting the parties to close the transaction. The parties have now obtained all regulatory approvals required to close the transaction and, accordingly, have scheduled a closing date of January 26, 2006. IVAX shareholders are advised that, given Read More »

Jerusalem, Israel, January 25, 2006 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that, subject to market and other conditions, it intends, through several special purpose finance subsidiaries, to offer $2.75 billion of debt securities comprised of: approximately $1.5 billion of senior notes in two series maturing in 2016 and 2036; approximately $750 million of convertible senior debentures maturing in 2026, which may be redeemed by Teva's finance subsidiary in five years and repurchased by Teva's finance subsidiary at investors' option in five, ten or fifteen years; Read More »

Strengthens Global Leadership in Generics, Adds New Product Lines and Growth MarketsJerusalem, Israel, January 26, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has completed its acquisition of IVAX Corporation (AMEX: IVX). The combined company, which will operate under the Teva name, will have a presence in over 60 countries and will employ approximately 26,000 people. The two companies generated over $7 billion in revenues for the twelve months ending September 30, 2005."This is a truly exciting day for us," said Israel Makov, Teva's President an Read More »

Jerusalem, Israel, January 27, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. District Court for the District of New Jersey has denied a motion filed by Aventis Pharmaceuticals, Inc. and Albany Molecular Research, Inc. for a preliminary injunction related to Teva's Fexofenadine Hydrochloride Tablets, the AB-rated generic equivalent of Aventis' antihistamine Allegra® Tablets.On September 6, 2005, Teva and Barr announced that they had entered into an agreement and launched the Fexofenadine Hydrochloride Tablet products. Under the agreement, Barr took the r Read More »

Jerusalem, Israel, January 27, 2006 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that it priced the offering, by its special purpose finance subsidiary, of $500 million of 5.550% senior notes maturing in 2016 and $1 billion of 6.150% senior notes maturing in 2036. These notes will be guaranteed by Teva. All of these securities are being offered pursuant to Teva's effective shelf registration statement, which was previously filed with the Securities and Exchange Commission and became effective on December 20, 2005. The offering of these senior notes is being made by a Read More »

Jerusalem, Israel, January 27, 2006 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that it priced its offering, through several special purpose finance subsidiaries, of $750 million of 1.75% convertible senior debentures maturing in 2026, which may be redeemed by Teva's finance subsidiary in five years and repurchased by Teva's finance subsidiary at investors' option in five, ten or fifteen years and $500 million of 0.25% convertible senior debentures maturing in 2026, which may be redeemed by Teva's finance subsidiary in two years and repurchased by Teva's finance sub Read More »